Gholami Sarah, Saffarfar Hossein, Mehraban Mohammad Reza, Ardabili Nastaran Safavi, Elhami Anis, Ebrahimi Sara, Ali-Khiavi Payam, Kheradmand Reza, Fattahpour Seyedeh Farinaz, Mobed Ahmad
Young Researcher and Elite Club, Islamic Azad University, Babol Branch, Babol, Iran.
Cardiovascular Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Breast Cancer Res Treat. 2025 Jun;211(3):561-580. doi: 10.1007/s10549-025-07696-5. Epub 2025 Apr 17.
Breast cancer is a leading cause of cancer-related mortality among women worldwide, characterized by its aggressive nature, propensity for metastasis, and resistance to standard treatment modalities. Traditional therapies, including surgery, chemotherapy, and radiation, often encounter significant limitations such as systemic toxicity and lack of specificity.
This review aims to evaluate the recent advancements in phage-based nanomedicines as a novel approach for targeted breast cancer therapy, focusing on their mechanisms of action, therapeutic benefits, and the challenges faced in clinical implementation.
A comprehensive literature review was conducted, analyzing studies that investigate the application of bacteriophages in cancer therapy, particularly in breast cancer. The review highlights the integration of nanotechnology with phage therapy, examining the potential for enhanced targeting and reduced side effects.
Phage-based nanomedicines have shown promise in selectively targeting breast cancer cells while sparing healthy tissues, thereby improving therapeutic efficacy and safety profiles. The unique properties of bacteriophages, including their ability to be engineered for specific targeting and their natural ability to induce immune responses, present significant advantages over conventional treatments.
The integration of phage therapy with nanotechnology represents a promising frontier in the fight against breast cancer. This review underscores the need for continued research to address existing challenges and to explore the full potential of phage-based nanomedicines in improving patient outcomes in breast cancer treatment.
乳腺癌是全球女性癌症相关死亡的主要原因，其特点是具有侵袭性、易于转移且对标准治疗方式具有抗性。传统疗法，包括手术、化疗和放疗，常常面临显著的局限性，如全身毒性和缺乏特异性。
本综述旨在评估基于噬菌体的纳米药物作为一种新型靶向乳腺癌治疗方法的最新进展，重点关注其作用机制、治疗益处以及临床应用中面临的挑战。
进行了全面的文献综述，分析了研究噬菌体在癌症治疗，特别是乳腺癌治疗中的应用的研究。该综述强调了纳米技术与噬菌体疗法的结合，探讨了增强靶向性和减少副作用的潜力。
基于噬菌体的纳米药物已显示出在选择性靶向乳腺癌细胞同时保护健康组织方面的前景，从而提高了治疗效果和安全性。噬菌体的独特特性，包括其可被工程化用于特异性靶向的能力以及其诱导免疫反应的天然能力，相对于传统治疗具有显著优势。
噬菌体疗法与纳米技术的结合代表了对抗乳腺癌的一个有前景的前沿领域。本综述强调需要持续研究以应对现有挑战，并探索基于噬菌体的纳米药物在改善乳腺癌治疗患者预后方面的全部潜力。
